A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...